Sr. Rafael Jorreto
Presidente de la Federación Andaluza de Síndrome de Asperger.

Sus comentarios sobre los tratamientos biomédicos y específicos contra el
Laboratorio Great Plains son deshonestos y sin bases de peso. Lo invitamos a
que lea nuestra carta de respuesta a sus ofensas para que replantee sus
críticas ofensivas.

1. Es verdad que el Laboratorio Great Plains es uno de los pocos
laboratorios, pero no el único,  que se enfoca en el estudio de
anormalidades metabólicas para ayudar a pacientes con problemas del
desarrollo. El Laboratorio Great Plains  se dedica, especialmente, en el
bienestar de las personas con autismo y trastornos del desarrollo.
Efectuamos cada semana pruebas de confirmación en muestras divididas en dos
o tres partes, para asegurar la exactitud de niveles de los productos
evaluados en la prueba de ácidos orgánicos. Se emplea el método de
cromatografía de gas y espectrometría de masa, el método más preciso para
detectar niveles de ácidos orgánicos. La Medición de cada producto está
individualmente verificada por un especialista técnico de laboratorio que
evalúa cada compuesto, comparándolo con el archivo ¨biblioteca¨¨ de
referencia para eliminar la posibilidad de falsos positivos. Para
cada compuesto analizado, se evalúan dos o tres iones. El Laboratorio Great
Plains está certificado para efectuar análisis especializados de alta
complejidad, está regularmente inspeccionado y conforma con todos los
criterios federales. Nuestro Laboratorio es el único laboratorio que tiene
patente oficial para la evaluación e interpretación de niveles de compuestos
de ácidos orgánicos, para el diagnóstico de disbiosis en autismo. Great
Plains está dedicado a las investigaciones en el ámbito de autismo y
regularmente emplea sus propios recursos a la investigación de nuevas causas
de autismo y al desarrollo de nuevas pruebas que ofrecerán mejores
soluciones a médicos, padres y personas afectadas. Los resultados de cada
prueba indican la escala de referencia normal, para los grupos de la edad
apropiada, lo que aumenta la pertinencia médica de los resultados.
El Dr. William Shaw, director del laboratorio, certificado
en química clínica y toxicología y tiene más de 20 años de experiencia
trabajando en laboratorios de gran prestigio. El Dr. Shaw fundó el
laboratorio Great Plains hace unos años por su interés personal en los temas
de autismo, déficit de atención e hiperactividad, para poder ofrecer
soluciones a las familias que tienen hijos o parientes que padecen estos

en desarrollar estas pruebas.
El Dr. William Shaw fundó este laboratorio con mucho
sacrificio, dejando un trabajo que ya tenía en un  hospital de gran
prestigio, el cual no le daba la oportunidad a dedicarse a la investigación
de las causas metabólicas de los trastornos del desarrollo.

2. El Laboratorio Great Plains está totalmente aprobado por CLIA
(Organización reguladora de Laboratorios Clínicos en Estados Unidos),
también participa en todas las evaluaciones anuales de eficiencia realizadas
por el Colegio de Patología Americana de laboratorios clínicos, para
comprobar la alta calidad de sus pruebas. Médicos calificados tanto
nacionalmente como internacionalmente, usan nuestros servicios para
diagnosticar problemas metabólicos, relacionados con trastornos del
desarrollo en sus pacientes.

3. En ningún momento decimos que nosotros "curamos" si esto es así le
pedimos que nos envíe algún documento (expedido por nosotros) en donde
aseguremos esto. El Laboratorio Great Plains trata de ayudar a "Mejorar la
Calidad de Vida" de pacientes con problemas de desarrollo, algunos de ellos
han progresado tanto que se han curado, no solo por los tratamientos
biomédicos, si no por la combinación de tratamientos. El costo de pruebas es
el mínimo que podemos ofrecer sin perder dinero y seguir funcionando. A esto
pueden sumar horas que pasamos hablando con nuestros pacientes por teléfono
y respondiendo sus correos electrónicos, explicándoles los resultados, las
opciones de tratamientos y las recomendaciones GRATUITAMENTE, ya que sabemos
que los padre hacen grandes sacrificios para hacer los estudios y tratamos
de no dejarlos sin conocer las interpretaciones de los resultados. Además,
siempre tratamos de explicar las maneras más económicas para realizar estos
tratamientos. Somos el UNICO laboratorio que ofrece asesoría gratuita a sus
pacientes.


4. Nos parece inapropiado que ponga en tela de juicio el testimonio de
una de las madres que logró que su hijo se recuperara, ya que usted no
conoce a detalle la historia de su recuperación. El hijo de la madre del
niño que usted menciona en su carta con tanta propiedad, fue diagnosticado
con autismo después de intervenciones biomédicas  y educaciones el niño se
recuperó totalmente y esto fue confirmado por su médico. Existen videos y
otros documentos que muestran la recuperación de este paciente. Lo invitamos
a que viste esta página en donde encontrará videos de niños recuperados
gracias a los tratamientos biomédicos
http://www.autism-recoveredchildren.org/, la historia de Slater, es uno de
los mejores ejemplos de una recuperación.
Le podría dar muchísimos ejemplos de  personas (niños y
adultos) cuya vida ha cambiado gracias a la dieta, suplementos y estudios
que les ayudaron a detectar estos problemas.  Lo invitamos a que viste las
siguientes páginas tanto en inglés como en español para que vea los
comentarios de padres y de médicos:

http://www.greatplainslaboratory.com/autism-comments.html

http://www.greatplainslaboratory.com/spanish/autismcomments.asp


También queremos compartir con usted algunas referencias e información que
tal vez le puede servir de información en caso de que quiera atacarnos
nuevamente:

De los protocolos de atención.
El Instituto de investigaciones del Autismo, establecido en San Diego
California por el Dr. Bernard Rimbland en 1967, ha dedicado todos estos años
a investigar y promover el tratamiento del Autismo, desde un enfoque
nutricional y metabólico. Ha desarrollado el DAN por sus siglas en inglés
(acabemos con el autismo), y este movimiento abriga en su comité científico
a renombrados científicos que además son padres de personas con autismo y de
ahí el gran interés que los mueve, - a tratar de encontrar tratamientos
alternativos que mejoren su calidad de vida.

Uno de los pilares de este tratamiento es una dieta sin gluten y caseína.
Estas proteínas encontradas en la leche y en el trigo, son incompletamente
digeridas por las personas con autismo, convirtiéndolas en productos
intermedios llamados péptidos, que en este caso tienen actividad a nivel
cerebral pues son idénticos a la morfina y pasan la barrera hematocéfalica,
se alojan en los receptores opiáceos del cerebro y alteran la conducta de
estas personas severamente. (Autoagresión leve a severa, el desnudarse todo
el tiempo, encerrarse en si mismo, no tener contacto visual, etc). Existen
estudios publicados en boletines indexados médicos  acerca de esto que se
anotan aquí:

1. DohanDohan FC. Cereals and schizophreniaschizophrenia: data and
hypothesis.  Acta Psychiatr Scand.42: 125,1966.
2. DohanDohan FC. Schizophrenia: possible relationship to cereal grains
and celiacceliac disease. In: S Sankar, editor. Schizophrenia: Current
Concepts and Research. P.J.D.  Publications, Hicksville, NY pg 539, 1969.
3. DohanDohan FC. The possible pathogenic effect of cereal grains in
schizophreniaschizophrenia - Celiac disease as a model. Acta Neurol.31: 195,
1976.
4. DohanDohan FC et al. Relapsed schizophrenicsschizophrenics. More
rapid improvement on a milk and cereal-free diet.  Br.  J. Psychiatry
115:595, 1969.
5. Kinivsberg, A et al. Dietary Intervention in Autistic Syndromes.
Brain Dysfunction 3: 315-327,1990.
6. ReicheltReichelt K et al. GlutenGluten, milk proteins and autism:
dietary intervention effects on behavior and peptide secretion. Journal of
Applied Nutrition 42: 1-11, 1990.
7. ReicheltReichelt K et al. Biologically active peptide-containing
fractions in schizophreniaschizophrenia and childhood autism, Adv Biochem
Psychopharmacology 28: 627-43, 1981.
8. ReicheltReichelt K et al. Probable etiology and possible treatment
of childhood autism. Brain Dysfunction 4: 308-19, 1991.

9. ReicheltReichelt K et al. Nature and consequences of hyperpeptiduria
and bovine casomorphins found in autistic syndromes. Developmental Brain
Dysfunction 7: 71-85, 1994.
10. ReicheltReichelt K et al. Child autism: a complex disorder.
Biological Psychiatry 21: 1279-90, 1986.
11. ReicheltReichelt K et al. The effect of gluten-free diet on urinary
peptide excretion and clinical state in schizophreniaschizophrenia. Journal
of Orthomolecular Medicine 5: 1223-39, 1990.
12. ShattockShattock P et al. Role of neuropeptidespeptides in autism
and their relationships with classical neurotransmitters. Brain Dysfunction
3: 328-345,1990.
13. ShattockShattock P., Lowdon G. Proteins, Peptides and Autism. Part
2.  Implications for the Education and Care of People with Autism 4:
323-334, 1991.
14. CadeCade et al. The effect of dialysis and diet on
schizophreniaschizophrenia. In: Psychiatry: A World Perspective. Volume
3.Stefanis et al, editors. Elsevier Science Publishers. Pgs 494-500,1990.
15. Reichelt KI et al.  GlutenGluten, milk proteins and autism: Results
of dietary intervention on behavior and urinary peptide secretion.  J.
Applied Nutrition 42: 1-11, 1990.
16. ReicheltReichelt KI et al. Nature and consequences of
hyperpeptiduria and bovine casomorphins found in autistic syndromes.
Develop Brain Dysfunct 7: 71-85, 1994.
17. ReicheltReichelt KI et al. Probable etiology and possible treatment
of childhood autism. Brain Dysfunct 4: 308-319, 1991.
18. Greco L. From the neolithic revolution to gluten intolerance:
benefits and problems associated to the cultivation of wheatwheat. Posted on
an Internet celiacceliac disease discussion group by Luigi Greco M.D., Dept
of Pediatrics, University of Naples, Naples, Italy. June 30,1995.
19. Torrey EF et al. Endemic psychosispsychosis in western Ireland. Am J
Psychiatry 141:  966-970, 1984.
20. Schmitz J. Coeliac disease in childhood. In Coeliac Disease. M
Marsh, editor. Blackwell Scientific Publications. Oxford, England. Pgs
19-22,1992

En cuanto al uso de nutrientes, vitaminas, ácidos grasos esenciales y su uso
en el autismo e hiperactividad, damos algunas referencias:

1. S Jill James, Paul Cutler, Stepan Melnyk, Stefanie Jernigan, Laurette
Janak, David W Gaylor and James A Neubrander. Increased oxidative stress and
impaired methylation capacity in children with autism: metabolic markers and
genetic predisposition. Defeat Autism Now Conference Proceedings, Fall
2004,pgs143-159.
2. Boris, M. The association of 5,10-methylene tetrahydrofolate reductase
gene polymorphisms with autistic spectrum disorders. Defeat Autism Now
Conference Proceedings, Fall 2004,pgs175-182.
3. Audhya T, McGinnis W. Nutrient, toxin, and enzyme profile of autistic
children. International Meeting for Autism Research, Sacramento, CA, May
7-8, 2004, p.74
4. Fatemi SH, Halt AR, Stary JM, Kanodia R, Schulz SC, Realmuto GR.Glutamic

acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal
and cerebellar cortices. Biol Psychiatry. 2002 Oct 15;52(8):805-10
5. Waly M, Olteanu H, Banerjee R, Choi SW, Mason JB, Parker BS, Sukumar S,
Shim S,Sharma A, Benzecry JM, Power-Charnitsky VA, Deth RC. Activation of
methionine synthase by insulin-like growth factor-1 and dopamine: a target
for neurodevelopmental toxins and thimerosal. Mol Psychiatry.  2004 Apr;
9(4):358-70.
6. Neubrander J. Biochemical context and clinical use of one specific member
of the five-member vitamin B-12 family, methylcobalamin. Defeat Autism Now
Conference Proceedings, Fall 2004,pgs 275-286.
7.Nieuwenhuizen WF, Pieters RH, Knippels LM, Jansen MC, Koppelman SJ. Is
Candida albicans a trigger in the onset of coeliac disease? Lancet. 2003 Jun
21; 361(9375):2152-4.
8.Krone CA, Elmer GW, Ely JT, Fudenberg HH, Thoreson J. Does
gastrointestinal Candida albicans prevent ubiquinone absorption? Med
Hypotheses. 2001 Nov;57 (5):570-2.
9. Kretschmar M, Klinger W. The hepatic glutathione systemÑinfluences of
xenobiotics. Exp Pathol 1990;38:145-164.
10. Ketterer B, Coles B, Meyer DJ. The role of glutathione in detoxication.
Environ Health Perspect 1983;49: 59-60.
11. Aldred S, Moore KM, Fitzgerald M, Waring RH. Amino acid abnormalities in
autism   Plasma amino acid levels in children with autism and their
families.J Autism Develop Disorders 33: 93-97,2003.
12. Zavala M, Ortega P, Montiel N.et al. Plasma amino acids in normal
children and children with autism. Proceedings of the Autism Society of
America Annual Conference, Milwaukee, WI, 1996, 243-246.
13. Choi D. Glutamate neurotoxicity and diseases of the nervous system.
Neuron 1:623-634,1988.
14. Erb J, Erb T. The slow poisoning of America. Paladins Press.Virginia
Beach, VA,2003,pgs.39-118.
15. Shao Y, Cuccaro ML, Hauser ER, Raiford KL, et al. Fine mapping of
autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes. Am
J Hum Genet. 2003 Mar;72(3):539-48. Epub 2003 Feb 03.
16. Menold MM, Shao Y, Wolpert CM, et al Association analysis of chromosome
15 gabaa receptor subunit genes in autistic disorder. J Neurogenet.
2001;15(3-4):245-59.
17.Jamain S, Betancur C, Quach H, et al. Linkage and association of the
glutamate receptor 6 gene with autism Mol Psychiatry. 2002;7(3):302-10.
18. Shaw, W., Kassen, E., and Chaves, E. 1995. Increased urinary excretion
of analogs of Krebs cycle metabolites and arabinose in two brothers with
autistic features. Clin. Chem. 41(8): 1094-1104.
19. Shaw, W., Kassen, E., and Chaves, E. Assessment of antifungal drug
therapy in autism by measurement of suspected microbial metabolites in urine
with gas chromatography-mass spectrometry. Clinical Practice of Alternative
Medicine: 15-26,2000.
20. James S, Culter P, Melnyk S et al Metabolic markers of increased
oxidative stress and impaired methylation capacity in children with autism.
American Journal of Clinical Nutrition, Vol. 80, No. 6, 1611-1617, December
2004
21. Potter MA, Luxton G. Prealbumin measurement as a screening tool for

protein calorie malnutrition in emergency hospital admissions: a pilot
study. Clin Invest Med. 1999 Apr;22(2):44-52.
22. Brusilow S. Determination of urine orotate and orotidine and plasma
ammonium. In: Techniques in Diagnostic Human Biochemical Genetics. A
Laboratory Manual. F Hommes, editor. Wiley Liss, 1991.pg.345.
23. Sweetman L. Organic acid analysis. In: Techniques in Diagnostic Human
Biochemical Genetics. A Laboratory Manual. F Hommes, editor. Wiley Liss,
1991.pgs 143-176.
24. Orotic acid. Pediatric Clinical Chemistry. Second edition. Samuel
Meites, editor. American Association of Clinical Chemistry, 1981. pg. 335
25.Rimland B. The use of vitamin B6, magnesium, and DMG in the treatment of
autistic children and adults. Biological Treatments for Autism and PDD.
Second Edition.
26. Martineau J, Garreau B, Barthelemy C, Callaway E, Lelord G.  Effects of
vitamin B6 on averaged evoked potentials in infantile autism. Biol
Psychiatry. 1981 Jul;16(7):627-41.
27.  Burd L, Stenehjem A, Franceschini LA, Kerbeshian J. A 15-year follow-up
of a boy with pyridoxine (vitamin B6)-dependent seizures with autism, breath
holding, and severe mental retardation. J Child Neurol. 2000
Nov;15(11):763-5.
28. Groff J and Gropper S. Advanced Human Nutrition, 3rd ed. Wadsworth
Thomson Learning, United Kingdom, 2000.pg  304-311.   
29. Birrer RB, Shallash AJ, Totten V. Hypermagnesemia-induced fatality
following epsom salt gargles. J Emerg Med. 2002 Feb;22(2):185-8.
30.Katrina M Wyatt, Paul W Dimmock, Peter W Jones and P M Shaughn O'Brien
Efficacy of vitamin B-6 in the treatment of premenstrual syndrome:
systematic review. BMJ;318;1375-1381, 1999
31. McGinnis W.  Oxidative stress in autism. Alternative
Therapies10:22-37,2004.29.
32. Zoroglu SS, Armutcu F, Ozen S, Gurel A, Sivasli E, Yetkin O, Meram I.
Increased oxidative stress and altered activities of erythrocyte free
radical scavenging enzymes in autism. Eur Arch Psychiatry Clin Neurosci.
2004 Jun;254(3):143-7.
33. Dolske MC, Spollen J, McKay S, Lancashire E, Tolbert L. A preliminary
trial of ascorbic acid as supplemental therapy for autism. Prog
Neuropsychopharmacol Biol Psychiatry. 1993 Sep;17(5):765-74.
34. Michael G. Chez, Cathleen P. Buchanan, Jamie L. Komen, and Marina
Becker, Double-Blind, Placebo-Controlled Study of L-Carnosine
Supplementation in Children with Autistic Spectrum Disorders.
http://www.carn-aware.com/online-store/scstore/index.html
35. Hagen TM, Wierbicka  GT, Sillau AH. Et al. Bioavailability of dietary
glutathione: effect on plasma concentration. Am J Physiol.  259: G524-529,
1990.
36. Chauhan A, Chauhan V, Brown WT, Cohen I.  Oxidative stress in autism:
increased lipid peroxidation and reduced   serum levels of ceruloplasmin and
transferrin--the antioxidant proteins. Life Sci. 2004 Oct 8;75(21):2539-49.
37.Neubrander J. Biochemical context and clinical use of vitamin B-12.
Spring DAN 2003 Conference, Philadelphia, PA, May 17,2003 pgs103-117.
38.Persico AM, Militerni R, Bravaccio C, et al  Adenosine deaminase alleles
and autistic disorder: case-control and family-based association studies. Am

J Med Genet 2000 Dec 4;96(6):784-90
39. Hirschhorn R, Roegner V, Rubinstein A, Papageorgiou P. Plasma
deoxyadenosine, adenosine, and erythrocyte deoxyATP are elevated at birth in
an adenosine deaminase-deficient child. J Clin Invest. 1980
Mar;65(3):768-71.
40. Hershfield MS Apparent suicide inactivation of human lymphoblast
S-adenosylhomocysteine hydrolase by 2'-deoxyadenosine and adenine
arabinoside. A basis for direct toxic effects of analogs of adenosine. . J
Biol Chem 1979 Jan 10;254(1):22-5
41. Theodore Page, Alice Yu, John Fontanesi, and William L. Nyhan.
Developmental disorder associated with increased cellular nucleotidase
activity Proc. Natl. Acad. Sci. USA Vol. 94, pp. 11601-11606, October 1997
42. Zia Fazili and Christine M. Pfeiffera Measurement of Folates in Serum
and Conventionally Prepared Whole Blood Lysates: Application of an Automated
96-Well Plate Isotope-Dilution Tandem Mass Spectrometry Method Clinical
Chemistry. 2004;50:2378-2381.
43. Shaw, W. 1988.  Possible synergistic effects of nonesterified fatty
acids and lysolecithins, a toxic methionine metabolite, and ammonia in the
production of hepatic encephalopathy and schizophrenia.   Orthomolecular
Medicine 3: 87.
44. Jackob Moskovitz, Shoshana Bar-Noy, Wesley M. Williams, Jesus Requena,
Barbara S. Berlett, and Earl R. Stadtman  Methionine sulfoxide reductase
(MsrA) is a regulator of antioxidant defense and lifespan in mammals.
45.Krone CA, Elmer GW, Ely JT, Fudenberg HH, Thoreson J. Does
gastrointestinal Candida albicans prevent ubiquinone absorption? Med
Hypotheses. 2001 Nov;57 (5):570-2.
46. Gulyaeva NV, Dupin AM, Levshina IP. Carnosine prevents activation of
free-radical lipid oxidation during stress. Bull Exp Biol Med.1989;
107(2):148-152.
47. Burgess JR, Stevens L, Zhang W, Peck L. Long-chain polyunsaturated fatty
acids in children with attention-deficit hyperactivity disorder.Am J Clin
Nutr. 2000 Jan;71(1 Suppl):327S-30S.
48.Vancassel S, Durand G, Barthelemy C, Lejeune B, Marineau J, Guilloteau D,
Andres C, Chalon S. Plasma fatty acid levels in   autistic children.
Prostaglandins Leukot Essent Fatty Acids 2001;65(1):1-7.
49. Richardson AJ, Ross MA. Fatty acid metabolism in neurodevelopmental
disorder: a new perspective on associations between
attention-deficit/hyperactivity disorder, dyslexia, dyspraxia and the
autistic spectrum. Prostaglandins Leukot Essent Fatty Acids. 2000
Jul-Aug;63(1-2):1-9.             
50. Bell JG, MacKinlay EE, Dick JR, MacDonald DJ, Boyle RM, Glen AC.
Essential fatty acids and phospholipase A2 in autistic spectrum   disorders.
Prostaglandins Leukot Essent Fatty Acids. 2004 Oct;71(4):201-4.
51. Bell JG, Sargent JR, Tocher DR, Dick JR. Red blood cell fatty acid
compositions in a patient with autistic spectrum disorder: a characteristic
abnormality in neurodevelopment disorders?   Prostaglandins Leukot Essent
Fatty Acids. 2000 Jul-Aug;63(1-2):21-5.
52. Johnson SM, Hollander E. Evidence that eicosapentaenoic acid is
effective in treating autism. J Clin Psychiatry. 2003 Jul;64(7):848-9.
53. Stoll A. The Omega-3 Connection. Simon and Schuster, NY, NY,2001, pg 216

54. .Jacobs M. et al. Time Trend Investigation of PCBs, PBDEs, and
Organochlorine Pesticides in Selected n-3 Polyunsaturated Fatty Acid Rich
Dietary Fish Oil and Vegetable Oil Supplements; Nutritional Relevance for
Human Essential n-3 Fatty Acid Requirements, April 7 edition of the Journal
of Agricultural and Food Chemistry Journal of Agricultural and Food
Chemistry April 7,2004.
55.Mercola J. Electronic newsletter. Secrets of the Edible Oil Industry
8/4/01
56. Enig M. Canola oil update. Optimal Wellness Health News. Electronic
newsletter. Issue 137 January 23, 2000
<http://www.mercola.com/2000/jan/23/index.htm>
http://www.mercola.com/index.htm            
57. WB Rizzo et al. Dietary erucic acid therapy for x-linked
adrenoleukodystrophy.   Neurology 1989 39: 141501422.
58. Byrnes S. I'VE GOT A LOVELY BUNCH OF COCONUTS, Coconut Holds Promise for
Immune Suppressed People, A & U Magazine, December 2000, and WellBeing
Magazine, June 2001
59. Mercola J. What Oil Should You be Cooking With, and Which Should You
Avoid? 10/15/03 http://www.mercola.com/index.htm.
60. Tierney E, Nwokoro NA, Kelley RI Behavioral phenotype of
RSH/Smith-Lemli-Opitz syndrome. Ment Retard Dev Disabil Res Rev
2000;6(2):131-4
61. Nwokoro NA, Mulvihill JJ Cholesterol and bile acid replacement therapy
in children and adults with Smith-Lemli-Opitz (SLO/RSH) syndrome. Am J Med
Genet 1997 Jan 31;68(3):315-21
62. Krakowiak PA, Nwokoro NA, Wassif CA, Battaile KP, Nowaczyk MJ, Connor
WE, Maslen C, Steiner RD, Porter FD   Mutation analysis and description of
sixteen RSH/Smith-Lemli-Opitz syndrome patients: polymerase chain
reaction-based assays to simplify genotyping. Am J Med Genet 2000 Sep
18;94(3):214-27
63. Walsh W.  Metallothionein deficiency in autistic spectrum disorders.
National Conference of The Autism Society of America. Seattle, Washington,
July 7-10,2004, p.342-349.
64. Knobeloch L, Ziarnik M, Howard J, Theis B, Farmer D, Anderson H, Proctor
M. Gastrointestinal upsets associated with ingestion of copper-contaminated
water. Environ Health Perspect. 1994 Nov;102(11):958-61.
65. Eife R, Weiss M, Barros V, Sigmund B, Goriup U, Komb D, Wolf W, Kittel
J, Schramel P, Reiter K. Chronic poisoning by copper in tap water: I. Copper
intoxications with predominantly gastrointestinal symptoms. Eur J Med Res
219-223
66. Eife R, Weiss M, Muller-Hocker M, Lang T, Barros V, Sigmund B, Thanner
F, Welling P, Lange H, Wolf W, Rodeck B, Kittel J, Schramel P, Reiter K.
Chronic poisoning by copper in tap water: II. Copper intoxications with
predominantly systemic symptoms. Eur J Med Res. 1999 Jun 28;4(6):224-8.
67. Araya M, Olivares M, Pizarro F, Gonzalez M, Speisky H, Uauy R.
Gastrointestinal symptoms and blood indicators of copper load in apparently
healthy adults undergoing controlled copper exposure. Am J Clin Nutr. 2003
Mar;77(3):646-50.
68. Hein MS. Copper deficiency anemia and nephrosis in zinc-toxicity: a case

report. S D J Med 2003 Apr;56(4):143-7.
69. Groff J and Gropper S.  Advanced Human Nutrition, 3rd ed. Wadsworth
Thomson Learning, United Kingdom, 2000.pgs. 430-440.
70. Groff J and Gropper S.  Advanced Human Nutrition, 3rd ed. Wadsworth
Thomson Learning, United Kingdom, 2000.pgs.419-430.
71. Clinical Guide to Laboratory Tests, 2nd edition, 1990, pg.116, edited by
N. Tietz. W.B. Saunders Co., Philadelphia
72. NCBI database. http://www.ncbi.nlm.nih.gov. Protein entries P80295 and
NP_005938.
73. Nordberg M, Nordberg GF. Toxicological aspects of metallothionein. Cell
Mol Biol 2000 Mar;46(2):451-63. 
74. Onosaka S, Tetsuchikawahara N, Min KS. Paradigm shift in zinc: metal
pathology. Tohoku J Exp Med. 2002 Jan;196(1):1-7.
75. Bush AI Metals and neuroscience. Curr Opin Chem Biol. 2000
Apr;4(2):184-91.
76. Giacconi R, Cipriano C, Muzzioli M, Gasparini N, Orlando F, Mocchegiani
E.   Interrelationships among brain, endocrine and immune response in ageing
and successful ageing: role of metallothionein III isoform. Mech Ageing Dev
2003 Apr;124(4):371-8
77. Grider A, Bailey LB, Cousins RJ. Erythrocyte metallothionein as an index
of zinc status in humans. Proc Natl Acad Sci U S A 1990 Feb;87(4):1259-62
78.  Tuthill RW. Hair lead levels related to children's classroom
attention-deficit behavior. Arch Environ Health 1996 May-Jun;51(3):214-20
Arch Environ Health 1996 May-Jun;51(3):214-20       
79. Lech T. Lead, copper, zinc, and magnesium content in hair of children
and young people with some neurological diseases. Biol Trace Elem Res. 2002
Feb;85(2):111-26
80.Toxicological Profile for Mercury. Catalog no. TP 93/10. Agency for Toxic
Substances and Disease Registry, Atlanta, GA. Pg 169
81.Grandjean P, Weihe P, White RF, Debes F, Araki S, Yokoyama K, Murata K,
Sorensen N, Dahl R, Jorgensen PJ.  Cognitive deficit in 7-year-old children
with prenatal exposure to  methylmercury. Neurotoxicol Teratol 1997
Nov-Dec;19(6):417-28.
82. Hac E, Krzyzanowski M, Krechniak J. Total mercury in human renal cortex,
liver, cerebellum and hair. Sci Total Environ 2000 Mar 29;248(1):37-43
83.Holmes A, Blaxill M, Haley B. Reduced levels of mercury in first baby
haircuts of autistic children. Int J Toxic 22: 277-285,2003.
84. Brewer G. Wilson disease and canine copper toxicosis. Am J Clin Nutr
1998;67(suppl):1087S-90S.(treatment, genetics, lab tests)
85. Johnson S.  Micronutrient accumulation and depletion in schizophrenia,
epilepsy, autism and
Parkinson's disease? Med Hypotheses. 2001 May;56(5):641-5.
86. Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, Sitterly J,
Fink JK. Treatment of Wilson disease with ammonium tetrathiomolybdate: III
Initial therapy in a total of 55 neurologically affected patients and
follow-up with zinc therapy. Arch Neurol 2003 Mar;60(3):379-85.         
87. Hermann W, Caca K, Eggers B, Villmann T, Clark D, Berr F, Wagner A.
Genotype correlation with fine motor symptoms in patients with Wilson's
disease. Eur Neurol. 2002;48(2):97-101.
88. Dening TR, Berrios GE: Wilson's disease: a longitudinal study of

psychiatric symptoms. Biol Psychiatry 1990; 28:255-265
89. Schoen RE, Sternlieb I: Clinical aspects of Wilson's disease. Am J
Gastroenterol 1990; 85:1453-1457
90.Kodama H, Murata Y, Kobayashi M. Clinical manifestations and treatment of
Menkes disease and its variants. Pediatr Int. 1999 Aug;41(4):423-9.
91.Wilson DC, Phillips MJ, Cox DW, Roberts EA. Severe hepatic Wilson's
disease in preschool-aged children. J Pediatr. 2000 Nov;137(5):719-22. 
92. Walker-Smith J and Andrews J. Alpha-1-antitrypsinAlpha-1-antitrypsin,
autism, and coeliac disease. The Lancet II: 883-884, 1972.
93. Bonaccorsi di Patti MC, Galtieri A, Giartosio A, Musci G, Calabrese L.
Dolphin ceruloplasmin: the first proteolytically stable mammalian
ceruloplasmin. Comp Biochem Physiol B. 1992 Sep;103(1):183-8.
94. Rae TD, Schmidt PJ, Pufahl RA, Culotta VC, O'Halloran TV. Undetectable
intracellular free copper: the requirement of a copper chaperone for
superoxide dismutase. Science. 1999 Apr 30;284(5415):805-8.
95. Fukuoka N, Morita S, Hamatani S, Okada H, Kondoh M, Imai T, Ohnishi S,
Itoh S. Yakugaku Zasshi 2002 Aug;122(8):585-8 Appropriate administration
schedule of D-penicillamine for pediatric Wilson's disease patients based on
urinary copper excretion.

Referencias de la presencia de cándida y bacteria en el intestino de las
personas con autismo.
1. Shaw W. Role for certain yeast and bacteria byproducts discovered by
organic acid testing in the etiology of a wide variety of human diseases.
American College for Advancement of Medicine Fall Convention. Anaheim, CA.
November 1997.
2. Shaw W. Exciting evidence to support a potential role for certain
yeasts and bacteria in the etiology of autism and other neurological
disorders.31st Annual Meeting of the American Academy of Environmental
Medicine. Boston, MA, October 1996.
3. Shaw, W and Chaves, E.  Experience with organic acid testing to
evaluate abnormal microbial metabolites in the urine of children with
autism. Keynote address. Published in The Proceedings of the Autism Society
of America National Conference on Autism. Milwaukee, WI, 1996.
4. Shaw, W., Chaves, E., and Luxem, M.  Abnormal urine organic acids
associated   with   fungal metabolism in urine samples of children with
autism: preliminary results of a clinical trial with antifungal drugs.
Published in The Proceedings of the Autism Society of America National
Conference on Autism. Greensboro, NC, July 1995.
5. Shaw, W. Organic acid testing:  abnormal metabolites in the urine of
children may assist in the diagnosis of, and   therapies   for autism.
Presented at   the Autism Society of America National   Conference on
Autism, Las Vegas, NV, July 1994.
6. Shaw, W., Kassen, E., and Chaves, E. Assessment of antifungal drug
therapy in autism by measurement of suspected microbial metabolites in urine
with gas chromatography-mass spectrometry. Clin Pract of Alt. Med:
15-26,2000.
7. Shaw, W., Kassen, E., and Chaves, E. 1995. Increased urinary
excretion of analogs of Krebs cycle metabolites and arabinose in two
brothers with autistic features. Clin. Chem. 41(8): 1094-1104.

Referencias de la presencia de metales pesados en los problemas de
aprendizaje y autismo

                        (1) ATSDR/EPA Priority List for 1999: Top 20
Hazardous
                        Substances, Agency for Toxic Substances and Disease
                        Registry, U.S. Department of Health and Human
Services,
                        http://www.atsdr.cdc.gov/99list.html; & United
States
                        Environmental Protection Agency, Office of Water,
                        November 2000, The National Listing of Fish and
Wildlife
                        Advisories: Summary of 1999 Data, EPA-823-F-00-20,
                        http://www.epa.gov/ost/fish/advisories/general.html;
&
                        Toxicological Effects of Methylmercury (2000), pp.
                        304-332: Risk Characterization and Public Health
                        Implications, Nat'l Academy Press, 2000,
www.nap.edu; &
                        U.S. Centers for Disease Control, Morbidity and
                        Mortality Weekly Report, Mar 2, 2001,
                        www.cdc.gov/mmwr/preview/mmwrhtml/mm5008a2.html.



                        (2) U.S. Environmental Protection Agency, Hazardous
Air
                        Pollutant Hazard Summary Fact Sheets, EPA: In Risk
                        Information System, 1995; & EPA spokesman, U.S. News
&
                        World Report, "In the Air That They Breathe",
Science &
                        News, 12-20-99; & U.S. Environmental Protection
Agency
                        (EPA), 1996, Integrated Risk Information System,
                        National Center for Environmental Assessment,
                        Cincinnati, Ohio (& web page); & EPA spokesman, U.S.

                        News & World Report, "Kids at Risk" (cover story),
                        6-19-2000.

                        (3) J.O. Nriagu, "Global metal pollution-Poisoning
the
                        biosphere", Environment,

                        Vol. 32, No. 7, Sept. 1990; & Shukla GS, Singhal RL,

                        "The present status of biological effects of toxic
                        metals in the environment: lead, cadmium, and

                        manganese", Can J Physiol Pharmacol, 1984 Aug,
                        62(8):1015-31; & Science News, Nov 6, 1986, P327-.

                        (4) Agency for Toxic Substances and Disease
Registry,
                        U.S. Public Health Service, "Toxicological Profile
for
                        Mercury", March 1999; & Apr 19, 1999 Media Advisory,
New
                        MRLs for toxic substances, MRL: elemental mercury
                        vapor/inhalation/chronic & MRL: methyl
                        mercury/oral/acute; &
                        http://www.atsdr.cdc.gov/mrls.html.

                        (5) Goyer RA, National Institute of Environmental
Health
                        Sciences, "Toxic and essential metal interactions",
Annu
                        Rev Nutr, 1997, 17:37-50; & "Nutrition and metal
                        toxicity", Am J Clin Nutr, 1995, 61(Suppl
3):646S-650S;
                        & Goyer RA, et al., "Environmental risk factors for
                        osteoporosis", Envir Health Perspectives, 1994,
                        102(4):390-394.



                        (6) Marlowe M, Cossairt A, Moon C, Errera J, "Main
and
                        interactive effects of metallic toxins on classroom
                        behavior", Journal of Abnormal Child Psychology,
1985,
                        13(2):185-98.



                        (6a) Marlowe M, Stellern J, Errera J, Moon C, "Main
and
                        interactive effects of metal pollutants on
visual-motor
                        performance", Arch Environ Health, 1985,
40(4):221-5.



                        (7) Pihl RO, Parkes M, "Hair element content in
learning
                        disabled children", Science, 1977 Oct 14,
                        198(4313):204-6.


                        (8) Moon C, Marlowe M, Stellem J, Errera J, "Main
and
                        interactive effects of metallic pollutants on
cognitive
                        functioning", Journal of Learning Disabilities,
1985,
                        18(4):217-221.



                        (9) Lewis M, Worobey J, Ramsay DS, McCormack MK,
                        "Prenatal exposure to heavy metals: effect on
childhood
                        cognitive skills and health status", Pediatrics,
1992,
                        89(6 Pt 1):1010-15.



                        (10) Capel ID, Pinnock MH, Dorrell HM, Williams DC,
                        Grant EC, "Comparison of concentrations of some
trace,
                        bulk, and toxic metals in the hair of normal and
                        dyslexic children", Clin Chem, 1981 Jun,
27(6):879-81; &
                        Frith CD, et al., "Dyslexia more common in English
                        speaking countries", Science, Mar 2001.



                        (11) Marlowe M, Errera J, Jacobs J, "Increased lead
and
                        cadmium burdens among mentally retarded children and

                        children with borderline intelligence", Am J Ment
Defic,
                        1983 Mar, 87(5):477-83; & Journal of Special
Education,
                        1982, 16:87-99.



                        (12)Thatcher RW, Lester ML, McAlaster R, Horst R,
                        "Effects of low levels of cadmium and lead on
cognitive
                        functioning in children", Arch Environ Health, 1982
                        May-Jun, 37(3):159-66.



                        (13) Marlowe M, Errera J, Cossairt A, Welch K, "Hair

                        mineral content as a predictor of learning
                        disabilities", Journal of Learning Disabilites,
1985.



                        (14) Marlowe M, Errera J, Jacobs J, "Increased lead
and
                        mercury levels in emotionally disturbed children",
                        Journal of Orthomolecular Psychiatry, 1983,
12:260-267;
                        & Journal of Abnormal Psychology, 1983, 93:386-9.



                        (15) Marlowe M, Moon C, Errera J, Jacobs J, "Levels
and
                        combinations of metallic toxins and measures of
                        behavioral disturbance, in: Rutherford RB (Ed.),
                        Monographs in Behavior Disorders, Vol. 5, p76-85,
                        Council for Children and Behavior Disorders, Reston
Va;
                        & Chisolm J, "Toxicity from heavy metal interactions
and
                        behavioral effects", Pediatrics, 1974, 53:841-43.



                        (16) Wecker L, Miller SB, Cochran SR, Dugger DL,
Johnson
                        WD, "Trace element concentrations in hair from
autistic
                        children", Defic Res, 1985, 29(Pt 1):15-22; & Zhai
ST,
                        "Trace element measurement in patients with
                        schizophrenia", Chung Hua Shen Ching Shen Ko Tsa
Chih,
                        1990, 23(6):332-8, 383.



                        (17) Rimland B, Larson GE, "Hair mineral analysis
and
                        behavior: An analysis of 51 studies", Journal of
                        Learning Disabilities, 1983, 16:279-85.



                        (18) Jiang HM, Han GA, He ZL, "Clinical significance
of
                        hair cadmium content in the diagnosis of mental
                        retardation of children", Chin Med J (Engl), 1990
Apr,
                        103(4):331-4.



                        (19) Great Smokies Diagnostic Lab, Developmental
                        Disorders of Toxic Origin: The

                        Persistence of Lead, 2000,

http://www.gsdl.com/news/insights/number4/index1.html; &
                        Emory E, Pattillo R, Archibold E, Bayorh M, Sung F,
                        "Neurobehavioral effects of low-level lead exposure
in
                        human neonates", Am J Obstet Gynecol, 1999,
181:S2-11; &
                        Mendelsohn AL, Dreyer BP, et al., "Low-level lead
                        exposure and behavior in early childhood",
Pediatrics,
                        1998, 101(3):E10.



                        (20) Bonithon-Kopp C, Huel G, Moreau T, Wendling R,
                        "Prenatal exposure to lead and cadmium and
psychomotor
                        development of the child at 6 years", Neurolbehav
                        Toxicol Teratol, 1986, 8(3):307-10.



                        (20a) David OJ, Hoffman SP, Sverd J, Clark K, Am J
                        Psychiatry, 1976, 133:1155; &

                        Perino J, Ernhart CB, Proc Annu Conv Am Psychol
Assoc,
                        1973, 81:719; & Leviton A,

                        Bellinger D, Allred EN, "Pre- and postnatal
low-level
                        lead exposure and children's dysfunction in school",

                        Environ Res, 1993, 60(1):30-43; & Eppright TD,
Samfacon


                        JA, and Horwitz EA, "ADHD, infantile autism, and
                        elevated blood level: a possible relationship", Mo
Med,
                        1996, 93(3):136-8; & Brockel BJ, Cory-Slechta DA,
"Lead,
                        attention, and impulsive behavior", Pharmacol
Biochem
                        Behav, 1998, 60(2):545-52; & Bellinger D, et al.,
                        "Attentional correlates of dentin levels in
adolescents,
                        Arch Environ Health, 1994, 49(2):8-105.



                        (20b) Deborah C. Rice, "Parallels between Attention
                        Deficit Hyperactivity Disorder and behavioral
deficits
                        produced by neurotoxic exposure in monkeys",
                        Environmental Health Perspectives, Volume 108,
                        Supplement 3, June 2000.



                        (21) Needleman HL, Riess JA, Tobin MJ, Biesecker GE,

                        Greenhouse JB, "Bone lead levels and delinquent
                        behavior", JAMA, 1996, 275(5):363-9; & Needleman HL,

                        Schell A, Bellinger D, Leviton A, Allred En, "The
                        long-term effects of exposure to low dose of lead in

                        childhood", N. England J Med, 1990, 322:83-88; &
                        Needleman HL, Leviton A, Reed R, "Deficits in
                        psychologic and classroom performance of children
with
                        elevated dentine lead levels", New Eng J Med, 1979,
                        300:689-95; & Burns ghurst PA, Sawyer MG, McMichael
Am,
                        Ton SL, "Lifetime low-level lead exposure to
                        environmental lead and children's emotional and
                        behavioral development at ages 11-13", Am J
                        Epidemiology, 1999, 149(8):740-49.



                        (22) Winneke G, Kramer U, et al.,
"Neuropsychological
                        studies in children with elevated tooth lead",
                        International Archives of Occupational Environmental

 

                        Health, 1983, 51:231-252; & de la Burde B, Dhoate M,

                        "Early asymptomatic lead exposure and development at

                        school age", Journal of Pediatrics, 1975,
87:638-642.



                        (23) Nancy Hallaway, Zigurts Strauts, Turning Lead
into
                        Gold : How Heavy Metal Poisoning Can Affect Your
Child
                        and How to Prevent and Treat It, 1995; & Dr. Bruce
                        Lanphear, Cincinnati Children's Hospital Medical
Center,
                        Annual Meeting of the Pediatric Academic Societies,
                        Baltimore, April, 2001,